Genevation LTD, individual Cancer vaccines

Welcome to Genevation LTD

Pioneering Personalized Cancer Vaccines

About Us

Welcome to Genevation, where we are revolutionizing cancer with our AI-driven, cell-free vaccine technology. Our unique sequencing method allows us to develop personalized mRNA cancer vaccines in just two weeks, significantly faster than traditional methods. By harnessing cutting-edge AI and innovative bio, we are setting a new standard in precision oncology. Join us on our mission to transform cancer care with, efficiency, and tailored solutions that can save lives.

Founded in 2022 in London, Genevation was born from a vision to harness cutting-edge science and technology to tackle one of the world's most complex health challenges: Cancer.

Our Science

At Genevation, science drives our mission to revolutionize cancer therapy and enhance lives. We believe that ground breaking discoveries can lead to transformative treatments, and our approach blends cutting-edge with deep scientific expertise. By harnessing the power of artificial intelligence, we precisely identify tumor-specific neoantigens, setting a new standard in personalized cancer care. With a focus on developing mRNA-based prophylactic and therapeutic vaccines for lung, colon, and skin cancers, we are committed to expanding our pipeline to address a wider array of cancer types.

our technology

Our Cutting-Edge Technology

Genevation leverages advanced platforms, including AI-driven neoantigen discovery and cell-free manufacturing, to innovate at every step of the therapeutic development process. By integrating artificial intelligence with molecular biology, we are at the forefront of precision oncology, creating tailored solutions that promise better outcomes for patients.

Biopsy/Blood Extraction

Studying mutations in cancer cells provides crucial insights into the disease and potential treatment options. By analyzing genetic alterations from patient biopsies, we can develop personalized treatments that specifically target the unique genetic makeup of each patient's cancer.

Mutation Identification

Genevation LTD employs an advanced, AI-driven Neoantigen Identification Platform to accelerate personalized cancer treatment development. By accurately identifying neo-antigens—unique proteins found on cancer cell surfaces—our platform provides critical insights that guide the creation of tailored cancer vaccines. This cutting-edge approach not only enhances research precision but also significantly improves the effectiveness of treatments, offering a transformative solution in the fight against cancer.

mRNA Delivery

Genevation LTD is revolutionizing cancer research with its personalized cancer vaccine pipeline. At the forefront of innovation, we are committed to pioneering new solutions to improve patient outcomes. Currently, we are rigorously evaluating pre-clinical studies targeting lung, skin, and colon cancers as we prepare for the transition to clinical trials, marking a pivotal step toward transformative cancer treatments.

Team

Meet Our Dedicated Team

At Genevation LTD, our team is a vibrant mix of talented professionals from diverse fields, all driven by a common mission: to save lives. With our expertise in science, biomedical engineering, bioinformatics, and AI development, we are to providing effective cancer treatments to every individual facing this challenging diagnosis. Together, we strive to make a meaningful difference in the fight against cancer, united by our passion and commitment to innovation.

Founder and CEO

Dr Prasun Chakraborty, PhD

With over 18 years of successful experience and expertise in IVT, Cancer biology, and RNA biology, as an ex-Harvard fellow, I have led successful oncology projects in both academia and industry. I have also served as a reviewer, speaker, and chair of many scientific panels, as well as a member and reviewer of scientific journals and community.

Our Pipelines

Our mRNA pipeline is making significant progress towards clinical trials, following the successful completion of a pre-clinical study targeting lung, colon, and skin cancers in mice. We are excited to announce our upcoming transition to Phase 1 clinical trials. Additionally, we are committed to expanding our pipeline to include other types of, including rare cancers, as we strive to make a meaningful impact on patient outcomes. Stay tuned for more updates on our journey!

Investor

Invest in Our Vision

We are looking for investors who share our unwavering passion for our work, and we welcome further investments to support our mission.

Latest Developments

Expanding Presence in the USA by 2026.

Careers

Explore Career Opportunities

Join Genevation LTD this summer for an exciting internship opportunity in genomics and bioinformatics! We're looking for motivated students and recent graduates, including Biomedical Engineers, AI and Data Scientists, and RNA Scientists. If you're passionate and eager to learn, we want to hear from you—college drop-outs are especially encouraged to apply! Send your CV and a brief note on why want to join our team to contact@genevation.co.uk.